Wall Street Journal - Peter Loftus - Jan 25, 2010
Provigil is expected to face generic competition in the US in 2012, while Nuvigil has patent protection through 2023. Earlier this month, Cephalon filed a ...
Revenue from Mepha will help Cephalon counter a sales decline after its top product, the sleep-disorder drug Provigil, loses patent protection in 2012. ...
In late 2005 and early 2006, the company entered into Provigil patent settlement agreements with four manufacturers in “pay-not-to-play” agreements. ...
Email this story
